SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME

Luke A.J. O'Neill; Rebecca Coll; Matthew A Cooper; Avril A B Robertson; Kate Schroder; Angus Murray Macleod; David John Miller

SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME

Luke A.J. O'Neill (Inventor), Rebecca Coll (Inventor), Matthew A Cooper (Inventor), Avril A B Robertson (Inventor), Kate Schroder (Inventor), Angus Murray Macleod (Inventor), David John Miller (Inventor)

School of Medicine, Dentistry and Biomedical Sciences

Research output: Patent

Abstract

The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: Formula (I) wherein Q is selected from O, S and Se; J is S or Se; W1 and W2, when present, are independently selected from N and C; R1 and R2 are independently selected from the group consisting of hydrogen, C1-C12alkyl, C2-C12alkenyl, C2-C12alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted; and wherein at least one of W1 and W2 is present and is a nitrogen atom and when R1 and R2 are cyclic then the respective W1 or W2 may form part of the ring structure. The present invention also relates to pharmaceutical compositions including such compounds, to methods of treatment using such compounds, in particular in relation to NLRP3 inflammasome mediated disorders, and to associated diagnostic uses.

Original language	English
Patent number	PCT/EP2017/053498
Priority date	16/02/2016
Filing date	16/02/2017
Publication status	Published - 24 Aug 2017

Access to Document

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017140778

Cite this

@misc{0b392a53a4e040fb882a74363551cf29,

title = "SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME",

abstract = "The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: Formula (I) wherein Q is selected from O, S and Se; J is S or Se; W1 and W2, when present, are independently selected from N and C; R1 and R2 are independently selected from the group consisting of hydrogen, C1-C12alkyl, C2-C12alkenyl, C2-C12alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted; and wherein at least one of W1 and W2 is present and is a nitrogen atom and when R1 and R2 are cyclic then the respective W1 or W2 may form part of the ring structure. The present invention also relates to pharmaceutical compositions including such compounds, to methods of treatment using such compounds, in particular in relation to NLRP3 inflammasome mediated disorders, and to associated diagnostic uses.",

author = "O'Neill, {Luke A.J.} and Rebecca Coll and Cooper, {Matthew A} and Robertson, {Avril A B} and Kate Schroder and Macleod, {Angus Murray} and Miller, {David John}",

year = "2017",

month = aug,

day = "24",

language = "English",

type = "Patent",

note = "PCT/EP2017/053498",

}

TY - PAT

T1 - SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME

AU - O'Neill, Luke A.J.

AU - Coll, Rebecca

AU - Cooper, Matthew A

AU - Robertson, Avril A B

AU - Schroder, Kate

AU - Macleod, Angus Murray

AU - Miller, David John

PY - 2017/8/24

Y1 - 2017/8/24

N2 - The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: Formula (I) wherein Q is selected from O, S and Se; J is S or Se; W1 and W2, when present, are independently selected from N and C; R1 and R2 are independently selected from the group consisting of hydrogen, C1-C12alkyl, C2-C12alkenyl, C2-C12alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted; and wherein at least one of W1 and W2 is present and is a nitrogen atom and when R1 and R2 are cyclic then the respective W1 or W2 may form part of the ring structure. The present invention also relates to pharmaceutical compositions including such compounds, to methods of treatment using such compounds, in particular in relation to NLRP3 inflammasome mediated disorders, and to associated diagnostic uses.

AB - The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: Formula (I) wherein Q is selected from O, S and Se; J is S or Se; W1 and W2, when present, are independently selected from N and C; R1 and R2 are independently selected from the group consisting of hydrogen, C1-C12alkyl, C2-C12alkenyl, C2-C12alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted; and wherein at least one of W1 and W2 is present and is a nitrogen atom and when R1 and R2 are cyclic then the respective W1 or W2 may form part of the ring structure. The present invention also relates to pharmaceutical compositions including such compounds, to methods of treatment using such compounds, in particular in relation to NLRP3 inflammasome mediated disorders, and to associated diagnostic uses.

M3 - Patent

M1 - PCT/EP2017/053498

Y2 - 2017/02/16

ER -

SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME

Abstract

Access to Document

Fingerprint

Cite this